|Product||Active Ingredients||Dosage form||Description||Launch date|
|Noxiall®||PEA + Commiphora Myrrha + Rosmarinus Officinalis + Piper Nigrum (of which Beta Caryophyllene)||Box of 20 tablets||Useful to contrast chronic and neuropathic pain||Jan 2017|
|Partnena®||Magnesium + Parthenium + Andrographis Paniculata + Coenzyme Q10 + Vitamin B2||Box of 28 tablets||Rational combination for the prophylaxis of migraine, the nociceptive modulation and the reduction of tension states||Jan 2014|
|Quetidia®||L-Theanine + Passiflora + Skullcap + Magnesium||Box of 30 tablets||Useful for the management of anxiety disorders||Sep 2014|
|Quetidia® oral solution||L-Theanine + Passiflora + Skullcap + Magnesium||Oral solution. Bottle of 150 ml||Useful for the management of anxiety disorders||Sep 2017|
|Seripnol®||L-Theanine + Magnolia + Ziziphus + Melatonin||Box of 28 sachets||Useful to promote relaxation and sleep||Mar 2012|
|Seripnol® drops||L-Theanine + Melatonin + Magnolia + Ziziphus||Oral drops. Bottle of 30 ml||Useful to promote relaxation and sleep||Apr 2014
|Triadenor®||N-Acetyl-Cystein + S-Adenosyl -LMethionine + Folic Acid||Box of 16 tablets||Useful for the management of depressive disorders||Nov 2014|
|UMP + Folic Acid + B12||Uridine Monophosphate + Folic Acid + Vitamin B12||Box of 20 and 40 film-coated tablets||Useful for the treatment of spinal syndromes, neuralgias and polyneuropathies||Jul 2018|
|Vivifast®||Citicoline Cognizin® + Homotaurine + Vitamin E||Box of 20 tablets||Useful in the management of several types of cognitive disorders||Nov 2015|
|Viviflux®||Homotaurine + DHA + Folic Acid||Box of 20 capsules||Indicated for stroke primary and secondary prevention and for cerebrovascular disorders||Sep 2011|
|Vivimind®||Homotaurine||Box of 40 tablets||Intended to protect memory and cognitive functions in MCI patients||Nov 2010|
[S] Singular Generics
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.